Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Recipient : SIFI
Deal Size : Undisclosed
Deal Type : Merger
SIFI Merges into Faes Farma to Expand International Access to its Portfolio and Pipeline
Details : The Group will invest into the further development of Akantior (polihexanide) into existing and new geographies, as well as the development of polihexanide into additional orphan indications.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 10, 2025
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Recipient : SIFI
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, Hikma will be responsible for obtaining regulatory approval of Bilastine by the US Food and Drug Administration (FDA) and for the commercialisation of the product in the US following approval.
Product Name : Bilaxten
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 20, 2021
Lead Product(s) : Bilastine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Hikma Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
